Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
U.S. NIH awards grant for preclinical development of Talotrexin in combo therapy
September 8th, 2005
Hana Biosciences, Inc., (HNAB), a South San Francisco, California-based biopharmaceutical company focused on advancing cancer care, was awarded a $159,000 small business innovation research grant entitled "Development of PT-523 for the treatment of lung cancer" by the U.S. National Institutes of Health (NIH). The award will enable Hana Biosciences to expand preclinical studies of Talotrexin in combination with other therapeutic agents as a potential first-in-class therapeutic approach to treating various forms of cancer. "This grant will expand the growing body of evidence of Talotrexin's efficacy in combination with various novel cytotoxic and...
Source: Women's Health Weekly (2005-09-08)
|
